<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine involved in many inflammatory reactions and disorders, and it has become evident that it also affects <z:chebi fb="105" ids="17234">glucose</z:chebi> homeostasis </plain></SENT>
<SENT sid="1" pm="."><plain>The protein is produced by pancreatic beta cells and can promote the release of insulin </plain></SENT>
<SENT sid="2" pm="."><plain>It also modulates <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake, glycolysis and <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> in insulin target cells such as the adipocyte, myocyte and cardiomyocyte </plain></SENT>
<SENT sid="3" pm="."><plain>Possessing both immunological and endocrinological properties, MIF has been associated with the development of type 1 and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, and it may be important in the setting of islet transplantation </plain></SENT>
<SENT sid="4" pm="."><plain>The present review summarises our current knowledge, based on clinical and research data, on the impact of MIF on both physiological and pathological aspects of <z:chebi fb="105" ids="17234">glucose</z:chebi> metabolism </plain></SENT>
</text></document>